Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Efficacy and safety of ruxolitinib in regularly transfused patients with thalassemia: results from a phase 2a study.

Literature DB >> 29097381

Efficacy and safety of ruxolitinib in regularly transfused patients with thalassemia: results from a phase 2a study.

Ali T Taher¹, Zeynep Karakas², Elena Cassinerio³, Noppadol Siritanaratkul⁴, Antonis Kattamis⁵, Aurelio Maggio⁶, Stefano Rivella⁷, Norbert Hollaender⁸, Bruyère Mahuzier⁹, Brian Gadbaw¹⁰, Yesim Aydinok¹¹.

Abstract

Entities: Disease Species

Mesh：

Substances：
INCB018424
Pyrazoles

Year: 2017 PMID： 29097381 PMCID： PMC5757682 DOI： 10.1182/blood-2017-06-790121

Source DB: PubMed Journal: Blood ISSN： 0006-4971 Impact factor: 22.113

× No keyword cloud information.

7 in total

1. Decreased differentiation of erythroid cells exacerbates ineffective erythropoiesis in beta-thalassemia.

Authors: Ilaria V Libani; Ella C Guy; Luca Melchiori; Raffaella Schiro; Pedro Ramos; Laura Breda; Thomas Scholzen; Amy Chadburn; YiFang Liu; Margrit Kernbach; Bettina Baron-Lühr; Matteo Porotto; Maria de Sousa; Eliezer A Rachmilewitz; John D Hood; M Domenica Cappellini; Patricia J Giardina; Robert W Grady; Johannes Gerdes; Stefano Rivella
Journal: Blood Date: 2008-05-14 Impact factor: 22.113

2. Ruxolitinib versus standard therapy for the treatment of polycythemia vera.

Authors: Alessandro M Vannucchi
Journal: N Engl J Med Date: 2015-04-23 Impact factor: 91.245

Review 3. 2017 Clinical trials update in new treatments of β-thalassemia.

Authors: Alexandros Makis; Eleftheria Hatzimichael; Ioannis Papassotiriou; Ersi Voskaridou
Journal: Am J Hematol Date: 2016-11 Impact factor: 10.047

Review 4. The role of ineffective erythropoiesis in non-transfusion-dependent thalassemia.

Authors: Stefano Rivella
Journal: Blood Rev Date: 2012-04 Impact factor: 8.250

Review 5. Emerging EPO and EPO receptor regulators and signal transducers.

Authors: David Kuhrt; Don M Wojchowski
Journal: Blood Date: 2015-04-17 Impact factor: 22.113

6. beta-Thalassemia: HiJAKing Ineffective Erythropoiesis and Iron Overload.

Authors: Luca Melchiori; Sara Gardenghi; Stefano Rivella
Journal: Adv Hematol Date: 2010-05-19

7. Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis.

Authors: C N Harrison; A M Vannucchi; J-J Kiladjian; H K Al-Ali; H Gisslinger; L Knoops; F Cervantes; M M Jones; K Sun; M McQuitty; V Stalbovskaya; P Gopalakrishna; T Barbui
Journal: Leukemia Date: 2016-05-23 Impact factor: 11.528

7 in total

11 in total

Review 1. Beyond transfusion therapy: new therapies in thalassemia including drugs, alternate donor transplant, and gene therapy.

Authors: John Porter
Journal: Hematology Am Soc Hematol Educ Program Date: 2018-11-30

Review 2. Iron metabolism under conditions of ineffective erythropoiesis in β-thalassemia.

Authors: Stefano Rivella
Journal: Blood Date: 2018-11-06 Impact factor: 22.113

3. The unexpected impact of cabozantinib on red blood cells consumption in patients with transfusion-dependent thalassemia.

Authors: Silvia Costantini; Antonella Meloni; Anna Spasiano; Patrizia Cinque; Paolo Ricchi
Journal: Ann Hematol Date: 2022-03-05 Impact factor: 3.673

Efficacy and safety of ruxolitinib in regularly transfused patients with thalassemia: results from a phase 2a study.

1. Decreased differentiation of erythroid cells exacerbates ineffective erythropoiesis in beta-thalassemia.

2. Ruxolitinib versus standard therapy for the treatment of polycythemia vera.

Review 3. 2017 Clinical trials update in new treatments of β-thalassemia.

Review 4. The role of ineffective erythropoiesis in non-transfusion-dependent thalassemia.

Review 5. Emerging EPO and EPO receptor regulators and signal transducers.

6. beta-Thalassemia: HiJAKing Ineffective Erythropoiesis and Iron Overload.

7. Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis.

Review 1. Beyond transfusion therapy: new therapies in thalassemia including drugs, alternate donor transplant, and gene therapy.

Review 2. Iron metabolism under conditions of ineffective erythropoiesis in β-thalassemia.

3. The unexpected impact of cabozantinib on red blood cells consumption in patients with transfusion-dependent thalassemia.

Review 4. β-Thalassemia: evolving treatment options beyond transfusion and iron chelation.

5. Transferrin receptor 2 is a potential novel therapeutic target for β-thalassemia: evidence from a murine model.

6. JAK2V617F mutation in patients with β-thalassemia disease: prevalence and clinical characteristics.

Review 7. Advancing the care of β-thalassaemia patients with novel therapies.

Review 8. The Role of Iron in Benign and Malignant Hematopoiesis.

Review 9. Non-Transfusion-Dependent Thalassemia: An Update on Complications and Management.

Review 10. Innovative Treatments for Rare Anemias.